%0 Journal Article
%T INDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES Study.
%A Graber E
%A Baldwin HE
%A Fried RG
%A Rieder EA
%A Hebert AA
%A Del Rosso J
%A Kircik L
%A Stein Gold L
%A Harper JC
%A Alexis AF
%A Narayanan S
%A Koscielny V
%A Kasujee I
%J J Drugs Dermatol
%V 23
%N 2
%D 2024 Feb 1
%M 38306151
%F 1.608
%R 10.36849/JDD.SF405634
%X <B>BACKGROUND: </B>Concise patient-reported outcome (PRO) instruments addressing the consequences of facial acne vulgaris (AV) on patients&rsquo; functioning and activities of daily living (ADL) are needed.<BR><B>METHODS: </B>A 12-week, single-arm, prospective cohort study was conducted in patients &ge;9 years old with moderate/severe non-nodular facial AV prescribed sarecycline as part of usual care. The primary endpoint included AV-specific patient- and caregiver-reported outcomes assessed with the expert panel questionnaire (EPQ, developed by 10 experts using a Delphi method) in patients (&gt;12 years) and caregivers (for patients 9-11 years). Additional assessments included parental/caregiver perspectives on children&rsquo;s AV.<BR><B>RESULTS: </B>A total of 253 patients completed the study. Following 12-weeks of treatment, there were significant (P &le;.0001) changes from baseline in the proportion of patients responding that they never or rarely: felt angry (31.6%), worried about AV worsening (28.9%), had thoughts about AV (20.9%), had a certain level of worries about AV (38.7%), altered their social media/selfie activity (23.7%), had an impact on real-life plans due to AV (22.9%), made efforts to hide AV (21.3%), felt picked-on/judged due to AV (15.0%), were concerned about their ability to reach future goals due to AV (13.8%), or had sleep impacted due to AV (18.2%). No significant change from baseline was observed for parent/caregiver&rsquo;s understanding of the child&rsquo;s AV concerns, from both patient and parent/caregiver perspectives.<BR><B>CONCLUSIONS: </B>Over 12 weeks of AV management with oral sarecycline, patients reported significant reductions in AV-related effects on emotional/social functioning and ADL as measured by the EPQ, a simple PRO with potential for use in clinical practice. J Drugs Dermatol. 2024;23:1(Suppl 1):s4-11.